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Previous studies (1-3) demonstrated a signifi-
cant increase in number of microbodies (peroxi-
somes) and concomitant elevation in catalase
activity in male rat liver following administration
of ethyl-o, p-chlorophenoxyisobutyrate (clofibrate,
CPIB), a hypolipidemic drug that lowers serum
cholesterol and triglycerides in man (4) and in
experimental animals (5, 6) . Neither the signifi-
cance of microbody proliferation induced by
CPIB nor the nature of controlling mechanism(s)
involved is known, although a possible relation of
microbodies to lipid metabolism has been sug-
gested (7). That proliferation of hepatic micro-
bodies in rats is independent of hypolipidemia fol
lowing CPIB treatment, however, has been shown
in studies in which thyroidectomy abolished the
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hypolipidemic effect of CPIB but did not interfere
with the microbody proliferation and increase in
catalase activity (8) . Although a close parallelism
existed between catalase activity and numerical
increase in microbodies in male rat liver following
CPIB treatment (3), no such relationship was
observed in recent studies on acatalasemic (Csb)
mice given CPIB (9) . The marked increase in
microbodies in the livers of these mutant mice,
genetically deficient in catalase (10), was not
associated with any significant rise in catalase
activity (9). This observation of lack of elevation
of catalase, which is one of the principal enzymes
of microbodies (11), suggested that microbody
proliferation can be induced in rat liver in the
absence of significant catalase synthesis.In the present study, the effect of CPIB on
male rat liver was examined in combination with
(a) allylisopropylacetamide (AIA) which effi-
ciently blocks the synthesis of catalase (12) with
out interfering with the activity of previously
formed catalase, with (b) aminotriazole which
irreversibly inhibits catalase (13) without inter-
fering with its synthesis, and with (c) cyclohexi-
mide, a potent inhibitor of protein synthesis (14).
The data suggest that microbody proliferation in
the rat liver can be achieved by administering
CPIB even in the absence of significant catalase
synthesis or in the presence of an agent that irre-
versibly binds with catalase. The numerical in-
crease in microbodies observed under these experi-
mental conditions was attended with negligible
catalase activity in the livers . However, the micro-
body proliferation induced by CPIB was com-
pletely abolished by cycloheximide.
MATERIALS AND METHODS
Inbred male F-344 rats (A . R. Schmidt Co., Madison,
Wisconsin) weighing between 165-200 g were used in
these experiments. They were force-fed our standard
purified synthetic diet (15) containing 16% casein
(vitamin-free), 62.5% sucrose, 10% corn oil, 2.5%
vitamin mixture (Nutritional Biochemicals Corpora-
tion, Cleveland, Ohio), 4% salt mixture (USP XIV),
and 5% alphacel. The animals were fed by stomach
tube, 10 g of diet daily, administered in 2 equal doses.
This provided approximately 40 cal/day per animal,
and was considered to be adequate caloric intake for
maintenance of growth (16). The forced-feeding
technique was adopted to avoid the possible com-
plication of caloric deficiency, since the animals re-
ceiving allylisopropylacetamide (AIA) tended to be
slightly drowsy for 1-2 hr following each injection
and may not have taken adequate and uniform
amounts of a diet if given ad lib.
Chemicals, Dose, and Mode
'Of Administration
The distribution of rats into experimental groups
is indicated in Table I . CPIB (Ayerst Laboratories,
New York) was administered in a daily dose of 250
mg/kg body weight by stomach tube, along with the
diet. Allylisopropylacetamide (AIA) (Hoffman-La
Roche, Inc., Nutley, N. J.) dissolved in saline was
administered intraperitoneally in a dose of 200 mg/kg
body weight every 12 hr. 3-amino-1,2,4-triazole
(K & K Laboratories Inc ., Plainview, New York)
was dissolved in water and injected intraperitoneally
(1 gm/kg body weight) twice daily . Cycloheximide
(Sigma Chemical Co., St. Louis, Mo.) was given
intraperitoneally in a dose of 0.5 mg/kg body weight
every 12 hr.
Morphological and Biochemical Methods
From all groups, samples of liver were fixed for 1-2
hr in 2% osmium tetroxide buffered to pH 7.4 with
S-collidine (2,4,6-trimethylpyridine [Vaughn Inc .,
Memphis, Tenn.]), and embedded in Epon (15).
Sections were cut with glass knives on an LKB ultra-
microtome, stained with lead hydroxide (17), and ex-
amined with an RCA 3G electron microscope . For
catalase determinations, 1 g of liver in 4 ml of M/150
phosphate buffer was homogenized at 1-4 °C with 30
strokes in a Potter-Elvehjem homogenizer at 400 rpm .
Catalase activity was determined by the spectropho-
tometric method of Luck (18) after 24 hr of extrac-
tion. Total proteins were determined by the method
of Lowry et al. (19) .
RESULTS
Table I shows the alterations in catalase activity
and in liver weight in each of the experimental
groups. It is evident that the administration of
CPIB for 7 days increases markedly the catalase
activity in the liver. The liver catalase levels were
reduced to less than 5% of normal value, when
AIA was administered alone or in combination
with CPIB. Administration of AIA for I wk prior
to giving CPIB (Group V) had a similar effect on
the inhibition of catalase activity . The liver
weight, expressed as per cent of body weight,
increased significantly in animals given CPIB or
AIA individually or in combination .
In accord with previous studies (2, 3), done
with electron microscopy, significant increase in
the number of microbodies was observed in the
liver cells of rats given CPIB for I wk . Adminis-
tration of AIA alone produced no obvious signs of
liver cell degeneration or necrosis. The most con-
spicuous alterations were disorganization of the
parallel arrays of rough endoplasmic reticulum
with focal detachment of ribosomes, depletion of
glycogen, and prominent proliferation of smooth
endoplasmic reticulum (Figs. 1, 2). Although the
mitochondria showed no consistent abnormalities
in size or configuration, a few of them had con-
densations possibly of lipid or protein in their
matrix (Fig. 3) . The microbodies in the livers of
rats treated with AIA alone for 7 days (group III)
were somewhat smaller than normal and showed
no apparent increase in their number (Fig . 1).
The matrix of several microbodies appeared less
dense than in controls, and the nucleoids were
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227TABLE I
Alterations in Catalase Levels and Liver Weight in F-344 Male Rats
body weight) 2 X daily for 7
days
* All animals were fed 16% protein diet by stomach tube (see Methods) .
$ Sacrificed 12 hr after the last injection.
somewhat prominent (Fig. 4) . An occasional
microbody displayed discontinuities in the limiting
membrane, probably due to dissolution or rupture .
Despite the absence of significant catalase
activity (Table I) in rats given both AIA and
CPIB (Groups IV and V), the liver cells showed
typical increase in number of microbodies (Fig . 5),
comparable to that observed in rats treated with
CPIB alone. In addition to the increase in micro-
body number, there was extensive proliferation of
smooth endoplasmic reticulum similar to that
observed in the livers of rats treated either with
AIA or CPIB alone . Several microbodies were
irregular in size and shape but did not differ from
those resulting from CPIB treatment alone (2, 3) .
The catalase activity in the livers of rats treated
with aminotriazole and CPIB for 1 week and sacri-
ficed 12 hr after the last aminotriazole injection
(Group VII) was 10.8 units/mg protein . Though
aminotriazole binds irreversibly with catalase, it
did not inhibit the increase in number of micro-
bodies that typically occurs with CPIB treatment.
Administration of cycloheximide prevented almots
completely the increase in microbody number
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accompanying CPIB treatment. Sections of liver
from CPIB-treated rats given cycloheximide were
indistinguishable from those from rats given cyclo-
heximide alone ; the most conspicuous changes con-
sisted of enlargement of mitochondria and a
marked loss of granular endoplasmic reticulum .
Catalase activity in these groups was reduced to
approximately one-third the normal value.
DISCUSSION
Recent studies have demonstrated that in the
livers of male rats microbodies were increased in
number and altered in size and shape after the
administration of CPIB, a hypolipidemic drug
(1, 2) . That the increase in microbodies, induced
by CPIB, was associated with elevated levels of
hepatic catalase was shown in subsequent studies
(3). Current experiments in our laboratory,
utilizing the techniques outlined by Price et al.
(20) for determining the kinetics of catalase syn-
thesis and destruction in vivo, indicate that CPIB
increases considerably the rate of catalase synthe-
sis without affecting the rate of its degradation
Groups* No. of animalsl
Liver weight
(Mean t standard error)
Catalase units/mg protein
(Mean f standard error)
g/100 g body weight
I Controls, untreated 5 3 .8 f 0.1 40.2 ° 3 .8
II CPIB, 7 days 5 6 .2 f 0 .2 85.1 f 5 .9
III AIA (200 mg/kg body weight) 4 5.4 f 0 .2 3.8 f 0.5
IV
2 X daily for 7 days
AIA (200 mg/kg body weight) 4 7 .1 f 0 .1 4 .5 f 0 .4
V
daily + CPIB, 7 days
AIA (200 mg/kg body weight) 4 8.2 f 0 .3 4.7 f 0 .3
VI
2 X daily for 7 days followed by
AIA + CPIB for 7 days
Aminotriazole (1 g/kg body 3 4.1 +0 .2 2 .9 f 0 .7
VII
weight) 2 X daily, 7 days
Aminotriazole (1 g/kg body 3 5.1 f 0 .1 10.8 f 2 .3
weight) 2 X daily + CPIB, 7
days
3 4 .5 t 0 .3 15 .1 f 2 .1 VIII Cycloheximide (0.5 mg/kg
body weight) 2 X daily + CPIB,
3 4 .4 t 0.3 14 .9 f 1 .1 IX
7 days
Cycloheximide (0.5 mg/kgFIGURE 1 Portion of cytoplasm of liver cell of rat treated with allylisopropylacetamide for 7 days . The
microbodies (mb) are few in number. Single strands of rough endoplasmic reticulum show focal dilatation
and detachment of ribosomes (arrows). Proliferation of smooth endoplasmic reticulum (SER) was signifi-
cant. X 40,000 .
229FIGURES 2-4 Male rat liver treated with ally] isopropylacetamide for 7 days . Extensive areas of smooth
endoplasmic reticulum (SER) are present. Some of the mitochondria contain opaque material (Fig. 3,
arrow) in the center. The microbodies (mb) reveal somewhat lucent matrix and prominent nucleoids (nuc)
in Fig. 4. Fig. 2, X 40,000; Fig. 3 X 50,000; Fig. 4, X 88,000.FIGURE 5 Numerous microbodies (mb) are observed in the liver cells of rats treated simultaneously with
allylisopropylacetamide and CPIB for 7 days. X 16,000.
B B T E F DT 0 T E 8
	
2 3 1(J. Reddy, M. Chiga, and D. Svoboda, in prepa-
ration) .
The precise biological significance of micro-
body proliferation and of increased synthesis of
catalase in the liver induced by CPIB and the
regulatory mechanism(s) involved in the initia-
tion of these events are, however, not fully eluci-
dated. On the basis of the observation of Hoch-
stein and Ernster (21), Novikoff and Shin (7) sug-
gested a possible relationship of microbodies to
lipid metabolism. Since hemoproteins constitute a
group of powerful lipid peroxidation catalysts (22),
it is possible that the catalase of microbodies has
a similar effect and that the microbodies partici-
pate in the formation of hydroperoxides of cho-
lesterol esters (23). Under these circumstances, it
appeared attractive to formulate a working hy-
pothesis : that the increase in microbody number
and catalase activity in the liver is related to the
lowering of serum cholesterol levels following
CPIB treatment (2, 24) . However, this does not
appear to be the case since administration of CPIB
to thyroidectomized rats resulted in an increase
in microbody number and catalase activity (8),
although thyroidectomy has been shown to abol-
ish the hypolipidemic action of CPIB (25) . From
these and other studies (8, 25, 26) it is evident that
hepatic microbody proliferation resulting from
CPIB treatment is not only independent of the
hypolipidemic effect, but may be independent of
thyroxine displacement from plasma protein bind-
ing sites. Therefore, it is reasonable to assume that
hypolipidemia and microbody proliferation are
two independent effects of CPIB and that these
two effects may not be interrelated .
Because of the temporal association of increase
in number of microbodies with elevated levels of
hepatic catalase, the increase in microbody forma-
tion following CPIB was considered as an expres-
sion of enhanced synthesis of catalase enzyme (2),
since catalase was reported to constitute 40% of
microbody protein (11). Although there is a sig-
nificant increase in catalase synthesis following the
administration of CPIB (Reddy, Chiga, and
Svoboda, in preparation), the results of the present
investigation, as well as the observations in acata-
lasemic (Csb) mice treated with CPIB (9), do not
support the contention that the increased micro-
body population is an expression primarily of the
increase in catalase level. In the present studies,
when CPIB was administered to rats receiving
allylisopropylacetamide (AIA), an agent that
232
	
B 4 1 rL F N O T E S
blocks the synthesis of new catalase (20), the
increase in microbody number occurred even
though catalase activity in the liver was negligible.
It is apparent, therefore, that AIA completely
inhibits the elevated synthesis of catalase resulting
from CPIB treatment, but does not appear to
interfere with the increase in microbody forma-
tion. Analogous to these findings are the observa-
tions in acatalasemic mice treated with CPIB (9) .
In these mutant mice, genetically deficient in
catalase (10), microbody proliferation occurred
following the administration of CPIB, but the
increase in microbody number was not associated
with any increase in catalase activity (9).
De Duve and his associates (11) showed that
microbodies possess several enzymes necessary for
the production and destruction of hydrogen
peroxide and termed then "peroxisomes," to
indicate their biochemical potential. In addition
to catalase, microbodies were shown to contain
several oxidases such as D-amino acid oxidase
and L-a-hydroxy acid oxidase . According to
Azarnoff and Svoboda (27), while catalase activ-
ity is increased significantly in male rats treated
with CPIB, there is 80% reduction in activity of
D-amino and L-a-hydroxy acid oxidases . Conse-
quently, in the present experiments, the increased
number of microbodies in rats treated with AIA
and CPIB may also contain minimal amounts of
D-amino and L-a-hydroxy acid oxidases. This
situation might be identical with that of micro-
bodies of acatalasemic mice treated with CPIB
(9). It appears paradoxical, therefore, to have
numerous microbodies in the livers of rats treated
with AIA and CPIB (also in acatalasemic mice
given CPIB) while some of their principal en-
zymes, catalase and oxidases, are markedly re-
duced.
Because microbody proliferation can be induced
in the absence of significant catalase synthesis
and with low levels of oxidases (27; Reddy,
Chiga, and Svoboda, in preparation), the view
that microbody formation induced by CPIB is due
primarily to increased synthesis of catalase enzyme
may not be tenable, despite the fact that catalase
synthesis as well as total hepatic catalase activity
increases markedly with CPIB treatment. The
question of what then is the additional triggering
mechanism in initiating the microbody prolifera-
tion after CPIB treatment remains unanswered .
One possibility is that, in addition to increase
in catalase synthesis, CPIB might induce the syn-thesis of yet unidentified proteins that make up
between one-half and two-thirds of the total
microbody (peroxisome) proteins, and/or of iso-
citrate dehydrogenase, which has been shown
recently to contribute as much as 25% of the total
peroxisome proteins (28) . From the present stud-
ies, it is evident that cycloheximide, which inhibits
protein synthesis by stabilization of polyribosomes
(14), abolished completely the microbody pro-
liferation expected from CPIB . The observations
of Platt and Cockrill (29) and preliminary studies
in this laboratory indicate that the concentration
of isocitrate dehydrogenase increases in the livers
of rats treated with CPIB ; whether this bears any
temporal relation to increase in microbody number
remains to be investigated . De Duve and Baud-
hum (11) suggested that microbodies could par-
ticipate significantly in the oxidation of cytoplas-
mic NADH, which is generally oxidized by way
of electron shuttles involving an appropriate
mitochondrial oxidizing system and the corre-
sponding cell sap dehydrogenase . The increase in
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